Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab + FLOT in Perioperative Setting for Resectable Gastric and GEJ Adenocarcinoma
NCT06967987Phase 2Withdrawn
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jan 2026
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemarituzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Efficacy of FLOT + bemarituzumab at 6 months. Planned start Jan 2026; status: withdrawn.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06967987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967987.